Muzaffar Qazilbash

Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma Chimeric antigen receptor T-cell (CAR-T) therapy is a widely adopted treatment for relapsed/refractory non-Hodgkin lymphomas (NHLs)1. FDA-approved CAR-T products for large B-cell lymphoma (LBCL) inclu...

Sarah Cannon Transplant and Cellular Therapy Registry work led by Drs Rao and Battiwalla comparing bendamustine vs. Flu/Cy LD chemo prior to #CART in #Lymphoma. This was done during period of Flu shortage. No difference in OS, PFS, CRS, ICANS.
www.astctjournal.org/article/S266...

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study Talquetamab continued to demonstrate high overall response rates in heavily pretreated patients with relapsed or refractory multiple myeloma with longer follow-up in this post-hoc analysis. Overall re...

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet Haematology #mmsm #bmtsm www.thelancet.com/journals/lan...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity MicroabstractOur study evaluated the efficacy and safety of reduced-dose melphalan (Mel140) versus high-dose melphalan (Mel200) in 233 multiple myeloma patients undergoing first autologous stem cell t...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity - Clinical Lymphoma, Myeloma and Leukemia www.clinical-lymphoma-myeloma-leukemia.com/article/S215...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity MicroabstractOur study evaluated the efficacy and safety of reduced-dose melphalan (Mel140) versus high-dose melphalan (Mel200) in 233 multiple myeloma patients undergoing first autologous stem cell t...

Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity #mmsm #bmtsm www.clinical-lymphoma-myeloma-leukemia.com/article/S215...

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies - Journal of Hematology & Oncology Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM...

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm jhoonline.biomedcentral.com/articles/10....

Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable In less than a decade since their first approval, chimeric antigen receptor T-cell (CAR-T) therapies have moved into earlier lines of therapy, shifting administration from an inpatient to an outpat...

Full article: Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable www.tandfonline.com/doi/full/10....

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine www.nejm.org/doi/full/10....

Stem Cell Transplantation & Cellular Therapy Fellowship- UT MD Anderson Cancer Center

careercenter.asco.org/job/7623735/...

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study Key PointsD-R maintenance improved MRD-negative conversion rate in patients with NDMM who were MRD-positive after transplant vs R maintenance.PFS favored D

Dara+ Len vs. Len alone as maintenance post autoSCT in NDMM: the AURIGA study. Dara + Len was associated with a better MRD -ve conversion and 30-month PFS #bmtsm #mmsm doi.org/10.1182/bloo...

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine #mmsm #bmtsm @nejm.org www.nejm.org/doi/full/10....

Highlights of ASH 2024: Focus on Multiple Myeloma According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m...

Highlights of ASH 2024: Focus on Multiple Myeloma #ASH24 #mmsm #bmtsm opmed.doximity.com/articles/hig...

GMMG-HD7 trial: Isa-VRD vs. VRD in transplant-eligible NDMM, N=662, Significantly higher MRD -ve (66 vs. 48%) and longer PF (3-year PFS: 88 vs. 71%) with Isa-VRD #bmtsm #mmsm ascopubs.org/doi/10.1200/JC…

Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes Key Points. High sBCMA and high MTV predict for inferior outcomes and increased severity toxicities in RRMM treated with anti-BCMA CAR-TDiscrepant results

High serum BCMA level and high metabolic tumor volume measured by PET/CT predict inferior PFS in RRMM treated with anti-BCMA CAR-T. Poor correlation seen between the two tests #bmtsm #mmsm ashpublications.org/blood/articl...

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four diffe...

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. N=1304, Gain 1q seen in 43% patients, all others in <10%. t(4;14), del 17p (>20% cells) and Gain 1q => shorter PFS and OS #bmtsm #mmsm onlinelibrary.wiley.com/doi/10.1002/...

#ASH24 First-in-human, dose escalation study of ISB 2001 (BCMAxCD38xCD3 trispecific antibody) in RRMM. N=14, CRS: 71% (gr 1 or 2), ORR: 75%. #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Cevostamab (anti-FcR5H bispecific), in RRMM. N=167, prior LOT: 6, 57% with prior anti-BCMA Rx. EMD: 28%. ORR: 43% (60% in anti-BCMA-naive). Infections: 53.9% #mmsm #bmtsm #ASH24 ash.confex.com/ash/2024/web...

#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Phase II trial of Anito-cel in RRMM #mmsm #bmtsm N=58, ORR: 95%, CR: 62%, MRD- 10^-5: 92%, CRS: 84%, no delayed neurotoxicity #mmsm #bmtsm ash.confex.com/ash/2024/web...

#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...

The best books of 2024, as chosen by The Economist www.economist.com/culture/2024...

ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...

Culture as a Centuries-Long Game of Telephone (Published 2023) Martin Puchner’s new book is a forceful rebuke to those who argue that culture can be owned by groups, nations, religions or races.

CULTURE: The Story of Us, From Cave Art to K-Pop, by Martin Puchner: Book Review www.nytimes.com/2023/02/07/b...

The Dawn of Everything by David Graeber and David Wengrow review – inequality is not the price of civilisation An archaeologist and an anthropologist dismantle received wisdom about the way early societies operated

The Dawn of Everything by David Graeber and David Wengrow: Book Review @theguardian1.bsky.social www.theguardian.com/books/2021/o...

The Invention of Good and Evil: A World History of Morality. By Hanno Sauer. Book review @theeconomistevents.bsky.social www.economist.com/culture/2024...

Optimal infused CD34+ cell dose in NDMM patients undergoing upfront autoHCT: >2.5 × 106 cells/kg. Phenomenal work by #orenpasvolsky @mdanderson.bsky.social #mmsm #bmtsm www.nature.com/articles/s41...

Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p Despite tremendous advancements in multiple myeloma (MM) therapeutics, outcomes remain heterogeneous, heavily influenced by clinical and cytogenetic f…

Outcomes of upfront AutoHCT (b/w 2008-2018) in NDMM With Del 17p. N=115, median PFS: 19.9 months, median OS: 71.5 months #mmsm #bmtsm @mdanderson.bsky.social www.sciencedirect.com/science/arti...

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼

PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼

A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼

doi.org/10.1182/bloo...

#MedSky #HemeSky

📢 Out in the European Journal of Hematology 🙌🏼

Red cell aplasia is uncommon but causes significant morbidity 😭

Daratumumab is effective, well tolerated, and leads to rapid and sustained responses 💪🏼

doi.org/10.1111/ejh....

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier.

We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed

#Hemesky

An immigration fix to address the health care workforce crisis Former HHS Secretary Tom Price writes that the new Trump administration should update immigration laws to help the U.S. health care workforce crisis.

An immigration fix to address the health care workforce crisis: Use graduates of U.S. schools to fill much-needed medical jobs @statnews.bsky.social www.statnews.com/2024/11/25/i...